Health and Healthcare
For Boston Scientific And JNJ, The Stent Stats Get Worse
Published:
"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up in South Florida. Still, restoring luster to the popular deviceis likely to be an uphill battle," The Wall Street Journal reports.
Johnson & Johnson (JNJ) reported that sales of its drug-coated stents dropped 40% in the third quarter. For Boston Scientific (BSX), that number was 24%. Drug coated stents are much more expensive that the older, bare metal version, and they have a much higher profit margin.
But, new concerns about the chance that the drug-coated device can cause clots has lead patients to seek other treatments including the use of drugs to thin blood and open arteries. A little over a year ago, 90% of stents put into patients were drug-coated. That figure is down to 60%.
That is a lot of revenue and especially profit lost by the two companies. JNJ is fairly diversified beyond the stent business, about BSX less so.
Boston Scientific just laid off over 2,000 people. That may not be the end of it.
Douglas A. McIntyre
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
